Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Name

Click to order products descending

Display 15 Products per page

Zyvox
Read More
Pfizer developed Zyvox (linezolid) as the first oxazolidinone antimicrobial agent. The drug gained its first regulatory approval for the treatment of complicated skin and skin structure infections (cSSSI) in the US market in 2000.
June 19, 2015
Find out more
Zytiga
Read More
Zytiga (abiraterone acetate; Johnson & Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates involved in testosterone synthesis.
January 18, 2018
Find out more
Zyprexa
Read More
Zyprexa (Eli Lilly) contains the atypical antipsychotic olanzapine, which acts as an antagonist at the D2 and 5-HT2A receptors.
April 9, 2018
Find out more
Zykadia
Read More
Zykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK).
August 30, 2018
Find out more
Zydelig
Read More
Zydelig (idelalisib; Gilead) is an oral, highly selective inhibitor of the phosphoinositide 3-kinase (PI3K) isoform p110-delta. In vitro studies have demonstrated that Zydelig results in decreased phosphorylation Akt and other downstream effectors, an increase in poly (ADP-ribose) polymerase and caspase cleavage, and an induction of apoptosis.
January 31, 2019
Find out more
Zybrestat
Read More
Zybrestat (fosbretabulin tromethamine; Mateon Therapeutics) is a water-soluble prodrug of cis-combretastatin A4, originally isolated from the African bush willow (Combretum caffrum).
August 17, 2017
Find out more
Zulresso
Read More
Zulresso is SAGE Therapeutics’ proprietary intravenous formulation of brexanolone, which is an allosteric modulator of both synaptic and extra-synaptic GABA-A receptors.
March 29, 2019
Find out more
Zontivity Approval: Views on Efficacy/Bleeding and Projected Usage Survey

$599.00

Zontivity was approved (May 8, 2014) for use with clopidogrel/aspirin, its label was relatively benign, not reporting bleeding in the overall trial, which included stroke/TIA patients who had excessive bleeding with the drug, or in ACS trial, where there was also excessive bleeding.
May 13, 2014
Find out more
Zontivity
Read More
Zontivity (vorapaxar; Merck & Co) gained US and EU approval for the reduction of thromboembolic

events in secondary-prevention patients with a history of myocardial infarction (MI).
April 14, 2016
Find out more
Zoladex
Read More
Zoladex (goserelin; AstraZeneca/TerSera Therapeutics) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.”
January 18, 2018
Find out more
Zinbryta
Read More
Zinbryta is a humanized monoclonal antibody that selectively binds to the alpha chain (cluster of differentiation [CD]25) of the interleukin-2 receptor on activated T cells to prevent the immunoactivation of MS.
November 24, 2017
Find out more
Zevalin
Read More
Zevalin (ibritumomab tiuxetan; Acrotech Biopharma/Mundipharma) is an intravenous radioactive agent consisting of the murine monoclonal antibody (MAb) ibritumomab, which is covalently linked to the chelator tiuxetan.
January 30, 2019
Find out more
Zetia Franchise
Read More
Multiple combination products based on the same active compound are known as a drug franchise. Franchises exist to give physicians, as well as patients, different treatment choices and to help with issues such as pill burden and compliance.
June 22, 2018
Find out more
Zepsyre
Read More
Zepsyre (lurbinectedin; PharmaMar/Chugai) is a novel synthetic agent derived from the marine-derived alkaloid trabectedin that inhibits the transcription process.
August 17, 2017
Find out more
Zepatier
Read More
Zepatier is a once-daily, fixed-dose combination of Merck & Co’s second-generation protease inhibitor, grazoprevir, and the company’s NS5A inhibitor, elbasvir.
November 6, 2017
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *